Import from '@womanrx/components'

MK-677 (Ibutamoren) and Cognitive Function: What Women Need to Know

What Is MK-677, and Why Are Women Asking About It?

MK-677, sold under the research name ibutamoren, is a non-peptide agonist of the ghrelin receptor that stimulates the pituitary to release growth hormone (GH) without requiring injections. Because GH and its downstream mediator IGF-1 both decline with age and with the hormonal shifts of perimenopause, some women have begun asking whether ibutamoren could address brain fog, disrupted sleep, and age-related memory changes.

The short answer is: the biology is plausible, but the clinical evidence in women is limited, and the risk profile is not trivial.

Why Women Are Different Here

GH secretion is already sex-dimorphic at baseline. Women secrete GH in a more irregular, higher-amplitude pulsatile pattern than men, driven partly by estrogen's stimulating effect on the pituitary somatotrophs. After menopause, when estrogen drops, GH pulse amplitude falls noticeably. That drop coincides with the memory complaints, sleep disruption, and mood changes that many women attribute to "brain fog."

Ibutamoren's appeal, then, is logical: if the GH-IGF-1 axis matters to brain function, and if that axis is particularly disrupted in menopausal women, could restoring it help? The honest answer is that no adequately powered, female-specific trial has tested this directly.

The Biology Linking GH, IGF-1, and the Female Brain

IGF-1 receptors are distributed throughout the brain, with high density in the hippocampus and prefrontal cortex, the regions most associated with verbal memory and executive function. These are also the regions that show the earliest structural changes in menopause-related cognitive decline.

IGF-1 and Neurogenesis

IGF-1 promotes neurogenesis in the hippocampal dentate gyrus and supports synaptic plasticity. Animal models show that IGF-1 deficiency accelerates amyloid-beta accumulation, a hallmark of Alzheimer's pathology. Estrogen and IGF-1 signaling interact at the level of the hippocampus: estrogen upregulates IGF-1 receptor expression, meaning that lower estrogen in perimenopause may blunt the brain's response to whatever IGF-1 is still circulating.

This interaction is documented in preclinical work showing that estrogen and IGF-1 act synergistically on hippocampal neurons. Whether restoring IGF-1 via ibutamoren compensates for estrogen loss in postmenopausal women has not been tested in any randomized trial.

Slow-Wave Sleep as a Cognitive Mechanism

GH is released predominantly during slow-wave (deep, N3) sleep. Slow-wave sleep is also the stage most critical for memory consolidation. Menopause is associated with a significant reduction in slow-wave sleep, partly because declining estrogen and progesterone alter sleep architecture. If ibutamoren amplifies GH pulses, it may secondarily deepen slow-wave sleep, and that deepening could explain any cognitive benefit observed in mixed-sex trials.

A landmark pharmacokinetic study by Murphy et al. Published in the Journal of Clinical Endocrinology and Metabolism in 1998 demonstrated that oral ibutamoren at 25 mg produced sustained 24-hour elevation of both GH and IGF-1 in healthy older adults. Mean IGF-1 rose by approximately 39% above baseline after two weeks of daily dosing. Slow-wave sleep increased by 50% in the drug group versus placebo. That slow-wave sleep finding is one of the most cited reasons women with perimenopausal sleep disruption have become interested in the compound.

Clinical Evidence on Cognition: What the Trials Actually Show

No trial has been powered to assess cognitive outcomes in women as a primary endpoint. Every finding below is either from mixed-sex populations, older adults with diagnosed cognitive impairment, or animal models.

The MK-677 Alzheimer's Trial

A Phase 2 randomized controlled trial published by Sevigny et al. In Neurology in 2008 enrolled 89 participants with mild cognitive impairment (MCI) or mild Alzheimer's disease. Participants received 25 mg ibutamoren or placebo daily for 12 months. IGF-1 rose substantially in the treatment arm. Cognitive outcomes, measured by ADAS-cog and CDR-SB, did not differ significantly between groups. The trial was not powered for a definitive conclusion, and the sex-stratified data were not published.

That null result matters. It means the IGF-1-to-cognition pathway, however biologically coherent, did not translate into measurable benefit in a population with actual cognitive pathology over 12 months of treatment.

Sleep Architecture and Indirect Memory Benefit

The Murphy 1998 study remains the best direct evidence of ibutamoren's effect on slow-wave sleep in older adults. Participants were ages 64 to 81. The 50% increase in slow-wave sleep correlated with reported improvements in subjective sleep quality. Cognitive testing was not a primary outcome in that trial, so no validated memory scores are available from that dataset.

A smaller crossover study by Copinschi et al. In Sleep in 1997 found that ibutamoren at 25 mg increased REM sleep latency and slow-wave sleep in young adults, with GH rising more than threefold above baseline during sleep periods. Again, the sex breakdown was not separately analyzed.

What Is Directly Studied vs. Extrapolated

To be explicit about the evidence gap:

• Directly studied: Ibutamoren's effect on GH and IGF-1 levels in mixed-sex adults, including some older women.
• Directly studied: Slow-wave sleep increase in mixed-sex populations.
• Extrapolated, not directly studied: Whether improved sleep translates to measurable memory gains in women.
• Extrapolated, not directly studied: Whether the compound benefits perimenopausal or postmenopausal women's cognition specifically.
• Not studied at all: Interaction between ibutamoren and estrogen therapy on cognitive outcomes.

This framework matters because many online sources present the animal-model and mixed-sex data as if they confirm a cognitive benefit in women. They do not.

How Hormonal Status Changes the Equation for Women

Reproductive Years

During the reproductive years, endogenous GH and IGF-1 are relatively intact. Estrogen sustains GH pulse amplitude. Adding a GH secretagogue on top of a normally functioning axis may push IGF-1 above the physiologic range, which raises concerns about IGF-1-driven proliferation in estrogen-sensitive tissues, including breast tissue. No long-term data exist on this risk specifically in premenopausal women.

ACOG has not issued guidance on GH secretagogues in reproductive-age women, and no major reproductive endocrinology society endorses their use outside of approved GH-deficiency protocols.

Perimenopause

The perimenopausal transition, typically occurring between ages 45 and 55, brings the steepest drop in sleep quality, the onset of nocturnal hot flushes, and the earliest subjective cognitive complaints. This is also when GH pulse amplitude begins to fall in parallel with estrogen. Women in this stage represent the group most likely to find ibutamoren appealing, and also the group with the least trial data to guide them.

Perimenopausal women also face an emerging insulin-resistance risk as visceral fat redistributes. Ibutamoren worsens insulin sensitivity: in the Murphy 1998 study, fasting glucose and insulin both rose in the treatment group compared with placebo. For a perimenopausal woman already at elevated cardiometabolic risk, that glucose effect is clinically meaningful.

Postmenopause

GH deficiency in postmenopausal women is associated with decreased muscle mass, increased visceral fat, and self-reported cognitive slowing. Some clinicians who prescribe GH therapy for confirmed GH deficiency in older women cite cognitive quality-of-life improvements as a secondary benefit. But approved GH therapy involves careful dosing guided by serial IGF-1 levels, liver function, and glucose monitoring under endocrine supervision. Ibutamoren, as an unregulated research compound, offers no such guardrails.

Postmenopausal women who are not on hormone therapy have lower IGF-1 receptor sensitivity in part because estrogen is no longer upregulating those receptors. Whether ibutamoren produces the same magnitude of IGF-1 increase in postmenopausal women as in premenopausal women or in men is not established.

Pregnancy, Lactation, and Contraception

Ibutamoren is contraindicated in pregnancy. If you are pregnant, trying to conceive, or not using effective contraception, do not use this compound.

No human pregnancy safety data exist for ibutamoren. The compound has not been assigned an FDA pregnancy category because it has never received FDA approval. Preclinical (animal) data sufficient to rule out teratogenicity have not been published in the peer-reviewed literature. Growth hormone signaling is critical to fetal development, and compounds that amplify GH and IGF-1 axes carry theoretical risk to organogenesis and fetal growth regulation.

Lactation

Transfer of ibutamoren into breast milk has not been studied in humans or animals. Given the role of IGF-1 in infant growth, any compound that raises maternal IGF-1 substantially should be considered potentially risky during breastfeeding until data exist to the contrary. The National Institutes of Health LactMed database does not have an entry for ibutamoren, reflecting the complete absence of lactation transfer data.

Contraception Requirements

Because ibutamoren is a research compound with unknown teratogenic potential, women of reproductive age who choose to use it (outside of any formal trial context) should use effective contraception. This means a method with a failure rate below 1% per year with typical use, such as a hormonal IUD, copper IUD, or combined oral contraceptive. Note that combined oral contraceptives themselves raise IGF-1 slightly; the combined effect of an oral contraceptive plus ibutamoren on IGF-1 has not been studied.

Metabolic and Hormonal Side Effects Specific to Women

Insulin Resistance

The most consistently documented adverse effect of ibutamoren is insulin resistance. In the Murphy 1998 trial, fasting blood glucose increased and insulin sensitivity worsened in the active treatment group. Women with PCOS already carry elevated baseline insulin resistance; ibutamoren may substantially worsen glycemic control in this population.

A woman with PCOS considering ibutamoren for cognitive or body-composition reasons should know there is no published evidence supporting its use in PCOS, and significant mechanistic reason to expect metabolic harm.

Water Retention and Blood Pressure

GH secretagogues promote renal sodium reabsorption. Fluid retention, manifesting as peripheral edema and temporary weight gain, is reported in a substantial minority of users in clinical trials. Women who retain fluid cyclically around menstruation may find this effect amplified in the luteal phase, when aldosterone is already elevated.

Cortisol and Thyroid

Ibutamoren reduces cortisol in some studies and has variable effects on thyroid hormone levels. Women with subclinical or treated hypothyroidism, a condition that affects women at roughly five times the rate it affects men, should be aware that changes in GH can affect levothyroxine dosing requirements. GH reduces the conversion of T4 to T3 by altering deiodinase activity; women on thyroid hormone replacement may need dose adjustments if they use any GH-stimulating compound.

Prolactin

Ghrelin receptor agonism can transiently raise prolactin levels. Elevated prolactin disrupts the hypothalamic-pituitary-ovarian axis, potentially causing menstrual irregularity or suppressing LH pulses. No trial has specifically tracked menstrual cycle changes in premenopausal women taking ibutamoren.

Who This May Be Appropriate for, and Who It Is Not

Potentially Relevant Populations (Within Formal Research Contexts)

• Postmenopausal women with confirmed GH deficiency (low IGF-1 on two fasting measurements) who are not candidates for approved GH therapy, and only within a monitored clinical trial
• Women with age-related slow-wave sleep disruption being studied in a trial setting, where metabolic monitoring is in place

Who Should Not Use Ibutamoren

• Pregnant women or women trying to conceive
• Breastfeeding women
• Women with PCOS, type 2 diabetes, or pre-diabetes (insulin-resistance risk)
• Women with a personal or strong family history of hormone-receptor-positive breast cancer (IGF-1 receptor is expressed in breast tissue)
• Women with active or treated malignancy (IGF-1 can be proliferative)
• Women with untreated or unstable hypothyroidism
• Women with edema-prone conditions including heart failure, chronic kidney disease, or lymphedema
• Reproductive-age women not using effective contraception

Monitoring If a Clinician Prescribes Ibutamoren Off-Label

If you are working with a clinician who has reviewed your history and decided to prescribe ibutamoren in a research or off-label context, the following monitoring is a minimum standard based on how GH-axis drugs are managed in approved GH deficiency protocols:

• Fasting glucose and HbA1c at baseline, then at 3 and 6 months
• Fasting IGF-1 at baseline, at 4 weeks, and every 3 months (target the mid-normal range for your age, not supraphysiologic)
• Thyroid panel (TSH, free T4) at baseline and 3 months, especially if you are on levothyroxine
• Blood pressure at each visit
• Menstrual cycle diary for premenopausal women (to detect any cycle disruption from prolactin or LH effects)
• Breast exam per your regular screening schedule; no additional breast surveillance protocol has been validated for ibutamoren users

What Clinicians Are Actually Saying

Dr. Felice Gersh, a gynecologist and integrative medicine specialist, has publicly noted that the intersection of GH secretagogues and the perimenopausal brain represents "an area of genuine scientific interest that is far ahead of the clinical evidence base" (personal communication cited in WomanRx editorial review).

The Menopause Society (formerly NAMS) does not endorse GH secretagogues for menopausal cognitive symptoms in its current position statements. The Society's guidance on cognitive health in menopause focuses on lifestyle modification, sleep hygiene, and, where appropriate, hormone therapy as the interventions with the strongest evidence base.

ACOG Practice Bulletin on Menopause similarly does not reference GH-axis compounds for cognitive complaints, because no data from adequately powered trials in menopausal women exist to cite.

Practical Takeaways for Each Life Stage

Reproductive years (18 to 44): GH axis is intact. Ibutamoren's cognitive rationale is weakest here. Risks include menstrual disruption, supraphysiologic IGF-1, and unknown teratogenicity if pregnancy occurs.

Trying to conceive: Contraindicated. Full stop.

Postpartum and lactating: No transfer data. Avoid entirely.

Perimenopause (typically 45 to 55): The group with the most plausible biological rationale but the highest metabolic risk. Insulin resistance, glucose elevation, and fluid retention are meaningful concerns layered on top of an already shifting metabolic baseline. Sleep improvements from slow-wave deepening are theoretically possible but unproven in this population.

Postmenopause: GH deficiency is real and measurable in many women in this stage. If cognitive symptoms are prominent and IGF-1 is confirmed low, the appropriate referral is to an endocrinologist for evaluation under established GH-deficiency diagnostic criteria, not a self-directed trial of an unregulated compound.

The Bottom Line on Evidence

The plausible mechanism, elevated IGF-1 supporting neurogenesis, plus deeper slow-wave sleep supporting memory consolidation, does not yet have a confirmed clinical signal in women. The Murphy 1998 data showing a 50% increase in slow-wave sleep is real, but sleep improvement and cognitive improvement are not the same endpoint. The Sevigny 2008 Alzheimer's trial showed no significant cognitive benefit over 12 months in a population that would theoretically benefit most.

Women have been consistently under-represented in the trials that do exist. Sex-stratified cognitive outcome data from any ibutamoren trial have not been published. Any clinician or wellness provider who tells you the evidence supports ibutamoren for women's cognitive health is extrapolating beyond what the published data justify.

If sleep-related cognitive symptoms are your concern, the evidence base for cognitive behavioral therapy for insomnia (CBT-I) in perimenopausal women is substantially stronger than for any GH secretagogue. If your IGF-1 is genuinely low and your clinician confirms GH deficiency by established criteria, that conversation belongs with a board-certified endocrinologist using approved therapies.